Feature | March 19, 2014

First Human Totally Endoscopic Aortic Valve Replacements (TEAVR) Reported

Surgeons Describe First TEAVR Procedures

March 19, 2014 — Surgeons in France have successfully replaced the aortic valve in two patients without opening the chest during surgery. The procedure, using totally endoscopic aortic valve replacement (TEAVR), shows potential for improving quality of life of heart patients by offering significantly reduced chest trauma. It is described in The Journal of Thoracic and Cardiovascular Surgery.


TEAVR had not been feasible previously because of the currently available designs of stented tissue valves. The recent advent of sutureless bioprostheses mounted on a compressible self-expanding nitinol (nickel titanium) stent, was one of the key factors enabling the surgical team to perform this procedure. Implantation required less than 45 minutes in either patient. Sutureless substitutes are not yet available for the other cardiac valves, like the mitral valve.


“In our institution, we began by adopting the mini-sternotomy technique, involving a small incision through the sternum, as routine. We then transitioned to the right mini-thoracotomy approach, involving a small incision through the thorax, first under direct view, then with an endoscopic camera. Finally we adopted a totally endoscopic technique,” said lead author Marco Vola, M.D., Ph.D, of the Department of Cardiovascular Surgery, Centre Hospitalier Universitaire de Saint-Etienne, France.


“It is important to note that when performing TEAVR, a quick and safe conversion to mini-thoracotomy under direct view can be made if circumstances demand. This would still offer significantly reduced chest trauma,” he said.


In other fields, totally endoscopic surgery involved longer clamping and cardiopulmonary bypass (CPB) times during the learning curve. The investigators believe that clamping and CPB times were acceptable and that the learning curve could be shorter than reported for totally endoscopic coronary artery bypass grafting.


Enhancements such as endoscopic sizers, dedicated instruments for decalcification, and second-generation sutureless bioprostheses to simplify implantation, could improve the procedure further, Vola and his colleagues comment. Last but not least, surgical robots may offer additional benefits.


“These first procedures show that totally endoscopic sutureless aortic valve replacement is technically feasible. Further clinical experience and technical development are necessary to shorten operation times and to assess further the potential postoperative benefits of TEAVR,” said Vola.


For more information: www.jtcvsonline.org


Related Content

Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
Feature | Heart Valve Repair| July 28, 2015
Boston Scientific announced CE Mark and U.S. Food and Drug Administration (FDA) clearance for the Safari2 Pre-Shaped...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences
 

News | Heart Valve Repair| July 21, 2015
The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve...
ACC, health policy statement, heart team, cardiovascular health
Feature | Cardiovascular Surgery| July 17, 2015
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern...
Biotronik, TAVI device, BIOVALVE trial, Hamburg, Germany
News | Heart Valve Repair| July 14, 2015
Biotronik announced the completion of the BIOVALVE first-in-human trial for its new transcatheter aortic valve. Study...
CardiAQ, Edwards, acquire, acquisition, Fortis, TMVI, mitral valve replacement

CardiAQ Transcatheter Mitral Valve Implantation System image courtesy of CardiAQ Valve Technologies

Feature | Heart Valve Repair| July 13, 2015
Edwards Lifesciences Corp. announced that it has agreed to acquire CardiAQ Valve Technologies Inc., a privately held...
sentraheart lariet, LAA occlusion, FDA safety alert
Feature | Left Atrial Appendage (LAA) Occluders| July 13, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers and patients of reports of patient deaths...
Feature | Business| July 08, 2015
Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies| July 07, 2015
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab...
Overlay Init